<p>Natera, Inc.（纳斯达克代码：NTRA - 获取免费报告）内部人士 John Fesko 于 5 月 26 日（星期二）出售了 1,438 股该公司的股票。股票的平均售价为 202.84 美元，总价值为 291,683.92 美元。交易后，该内部人士直接持有 185,782 股公司股票，价值为 37,684,020.88 美元。这笔交易代表其持股比例下降了 0.77%。该出售在与 SEC 的法律文件中披露，相关信息可在 SEC 网站上查阅。该交易是在预先安排的 10b5-1 交易计划下执行的。出售的目的是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
<ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
<p>John Fesko 最近还进行了以下交易：</p>
<ul>
<li>5 月 1 日（星期五），John Fesko 出售了 291 股 Natera 股票。股票的平均售价为 206.16 美元，总价值为 59,992.56 美元。</li>
<li>4 月 27 日（星期一），John Fesko 出售了 1,688 股 Natera 股票。股票的平均售价为 204.10 美元，总价值为 344,520.80 美元。</li>
<li>3 月 10 日（星期二），John Fesko 出售了 707 股 Natera 股票。股票的平均售价为 204.13 美元，总价值为 144,319.91 美元。</li>
</ul>
<h2>Natera 股票表现</h2>
<p>NTRA 在星期四上涨了 10.83 美元，达到 213.94 美元。该公司交易了 1,861,579 股，相较于其平均交易量 1,650,189 股。该公司的 50 日简单移动平均为 201.85 美元，200 日简单移动平均为 215.63 美元。该股票的市值为 306.4 亿美元，市盈率为-131.25，贝塔值为 1.57。Natera, Inc.的 12 个月低点为 131.81 美元，12 个月高点为 256.36 美元。</p>
<ul>
<li>Myriad Genetics 因遗传癌症检测而股价飙升</li>
</ul>
<p>Natera（纳斯达克代码：NTRA - 获取免费报告）最后一次公布季度财报是在 2 月 26 日（星期四）。该医疗研究公司报告每股收益为 0.35 美元，超出市场共识预期的-0.46 美元，超出幅度为 0.81 美元。该公司在本季度的收入为 6.655 亿美元，而市场共识预期为 6.0068 亿美元。Natera 的股本回报率为-14.74%，净利润率为-9.05%。在去年同期，该公司每股收益为-0.41 美元。分析师平均预计 Natera, Inc.在当前年度的每股收益为-1.49 美元。</p>
<h2>机构投资者对 Natera 的看法</h2>
<p>一些大型投资者最近调整了对该股票的持有。Reflection Asset Management 在第四季度购买了 Natera 的新股份，价值约 29,000 美元。Palladiem LLC 在第四季度购买了 Natera 的新股份，价值约 31,000 美元。Jackson Hole Trust 在第四季度将其在 Natera 的持股增加了 103.8%。Jackson Hole Trust 现在拥有 163 股该医疗研究公司的股票，价值 37,000 美元，此前在上个季度又购买了 83 股。International Assets Investment Management LLC 在第一季度将其在 Natera 的持股增加了 132.9%。International Assets Investment Management LLC 现在拥有 170 股该医疗研究公司的股票，价值 35,000 美元，此前在上个季度又购买了 97 股。最后，Kemnay Advisory Services Inc.在第四季度购买了 Natera 的新股份，价值约 39,000 美元。机构投资者持有该公司 99.90% 的股票。</p>
<h2>分析师评级变动</h2>
<p>NTRA 最近受到了一些分析师报告的关注。摩根士丹利在 3 月 3 日的报告中将 Natera 的目标股价从 265.00 美元下调至 250.00 美元，并对该公司给予 “增持” 评级。摩根大通在 5 月 8 日的报告中将 Natera 的目标股价从 260.00 美元上调至 265.00 美元，并给予该股票 “增持” 评级。富国银行在 5 月 8 日的研究报告中将 Natera 的目标价从 215.00 美元上调至 220.00 美元，并给予该公司 “持平” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Natera 的 “卖出（d-）” 评级。最后，Robert W. Baird 在 5 月 8 日的报告中将 Natera 的目标价设定为 265.00 美元。一位分析师对该股票给予了强烈买入评级，十四位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 256.60 美元。</p>
<p><strong>查看我们对 NTRA 的最新分析</strong></p>
<h2>关于 Natera</h2>
<p>（获取免费报告）</p>
<p>Natera 是一家全球诊断公司，开发和商业化无细胞 DNA 及其他基因检测技术用于临床应用。该公司专注于三个主要领域：生殖健康（包括无创产前检测和携带者筛查）、肿瘤学（用于最小残留病和复发监测的肿瘤信息检测）以及器官移植（用于检测移植物损伤的无细胞 DNA 检测）。Natera 结合实验室检测、专有生物信息学和临床报告，为临床医生和患者提供个性化的基因信息。</p>
<p>主要产品包括 Panorama，一种无创产前检测，用于筛查胎儿染色体异常和特定单基因疾病；Horizon 携带者筛查，用于遗传疾病；Signatera，一种个性化的肿瘤信息检测，用于检测最小残留病和监测癌症患者的治疗反应；以及 Prospera，一种供体来源的无细胞 DNA 检测，用于评估器官排斥的风险。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Natera 更好</li>
<li>3 只因美光价格上涨而上涨的股票：实质还是炒作？</li>
<li>Snowflake 及其 AI 飞轮的滚雪球效应</li>
<li>AI 的最大瓶颈可能使这两只股票飙升</li>
<li>这三只被打压的股票刚刚看到 2500 万美元的内部购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Natera 吗？</h2>
<p>在考虑 Natera 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Natera 并不在名单上。</p>
<p>虽然 Natera 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NTRA

<p>Natera, Inc.（纳斯达克代码：NTRA）的内部人士 John Fesko 出售了 1,438 股，平均价格为 202.84 美元，总计 291,683.92 美元。交易后，他持有 185,782 股，价值约为 3,768 万美元，持股比例减少了 0.77%。此次出售是在一个 10b5-1 交易计划下进行的，以满足税务义务。Natera 的股票最近交易价格为 213.94 美元，市值为 306.4 亿美元</p>

<p>Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 1,438 shares of the firm's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total value of $291,683.92. Following the transaction, the insider directly owned 185,782 shares in the company, valued at $37,684,020.88. This trade represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Natera, Inc.（纳斯达克代码：NTRA - 获取免费报告）内部人士 John Fesko 于 5 月 26 日（星期二）出售了 1,438 股该公司的股票。股票的平均售价为 202.84 美元，总价值为 291,683.92 美元。交易后，该内部人士直接持有 185,782 股公司股票，价值为 37,684,020.88 美元。这笔交易代表其持股比例下降了 0.77%。该出售在与 SEC 的法律文件中披露，相关信息可在 SEC 网站上查阅。该交易是在预先安排的 10b5-1 交易计划下执行的。出售的目的是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
</div><p>John Fesko also recently made the following trade(s):</p>
<div class="lb-trans"><p>John Fesko 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $59,992.56.</li>
<li>On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $344,520.80.</li>
<li>On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $144,319.91.</li>
</ul>
<div class="lb-trans"><ul>
<li>5 月 1 日（星期五），John Fesko 出售了 291 股 Natera 股票。股票的平均售价为 206.16 美元，总价值为 59,992.56 美元。</li>
<li>4 月 27 日（星期一），John Fesko 出售了 1,688 股 Natera 股票。股票的平均售价为 204.10 美元，总价值为 344,520.80 美元。</li>
<li>3 月 10 日（星期二），John Fesko 出售了 707 股 Natera 股票。股票的平均售价为 204.13 美元，总价值为 144,319.91 美元。</li>
</ul>
</div><h2>Natera Stock Performance</h2>
<div class="lb-trans"><h2>Natera 股票表现</h2>
</div><p>NTRA traded up $10.83 on Thursday, hitting $213.94. 1,861,579 shares of the company were exchanged, compared to its average volume of 1,650,189. The firm has a fifty day simple moving average of $201.85 and a two-hundred day simple moving average of $215.63. The stock has a market capitalization of $30.64 billion, a PE ratio of -131.25 and a beta of 1.57. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36.</p>
<div class="lb-trans"><p>NTRA 在星期四上涨了 10.83 美元，达到 213.94 美元。该公司交易了 1,861,579 股，相较于其平均交易量 1,650,189 股。该公司的 50 日简单移动平均为 201.85 美元，200 日简单移动平均为 215.63 美元。该股票的市值为 306.4 亿美元，市盈率为-131.25，贝塔值为 1.57。Natera, Inc.的 12 个月低点为 131.81 美元，12 个月高点为 256.36 美元。</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遗传癌症检测而股价飙升</li>
</ul>
</div><p>Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the previous year, the company posted ($0.41) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Natera（纳斯达克代码：NTRA - 获取免费报告）最后一次公布季度财报是在 2 月 26 日（星期四）。该医疗研究公司报告每股收益为 0.35 美元，超出市场共识预期的-0.46 美元，超出幅度为 0.81 美元。该公司在本季度的收入为 6.655 亿美元，而市场共识预期为 6.0068 亿美元。Natera 的股本回报率为-14.74%，净利润率为-9.05%。在去年同期，该公司每股收益为-0.41 美元。分析师平均预计 Natera, Inc.在当前年度的每股收益为-1.49 美元。</p>
</div><h2>Institutional Investors Weigh In On Natera</h2>
<div class="lb-trans"><h2>机构投资者对 Natera 的看法</h2>
</div><p>A number of large investors have recently modified their holdings of the stock. Reflection Asset Management bought a new stake in Natera during the fourth quarter worth about $29,000. Palladiem LLC bought a new stake in Natera during the fourth quarter worth about $31,000. Bank of Jackson Hole Trust boosted its stake in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after acquiring an additional 83 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in Natera during the fourth quarter worth about $39,000. Institutional investors own 99.90% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该股票的持有。Reflection Asset Management 在第四季度购买了 Natera 的新股份，价值约 29,000 美元。Palladiem LLC 在第四季度购买了 Natera 的新股份，价值约 31,000 美元。Jackson Hole Trust 在第四季度将其在 Natera 的持股增加了 103.8%。Jackson Hole Trust 现在拥有 163 股该医疗研究公司的股票，价值 37,000 美元，此前在上个季度又购买了 83 股。International Assets Investment Management LLC 在第一季度将其在 Natera 的持股增加了 132.9%。International Assets Investment Management LLC 现在拥有 170 股该医疗研究公司的股票，价值 35,000 美元，此前在上个季度又购买了 97 股。最后，Kemnay Advisory Services Inc.在第四季度购买了 Natera 的新股份，价值约 39,000 美元。机构投资者持有该公司 99.90% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>NTRA has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, March 3rd. JPMorgan Chase &amp; Co. raised their price target on shares of Natera from $260.00 to $265.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, May 8th. Wells Fargo &amp; Company boosted their price objective on shares of Natera from $215.00 to $220.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Natera in a research note on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $256.60.</p>
<div class="lb-trans"><p>NTRA 最近受到了一些分析师报告的关注。摩根士丹利在 3 月 3 日的报告中将 Natera 的目标股价从 265.00 美元下调至 250.00 美元，并对该公司给予 “增持” 评级。摩根大通在 5 月 8 日的报告中将 Natera 的目标股价从 260.00 美元上调至 265.00 美元，并给予该股票 “增持” 评级。富国银行在 5 月 8 日的研究报告中将 Natera 的目标价从 215.00 美元上调至 220.00 美元，并给予该公司 “持平” 评级。Weiss Ratings 在 4 月 21 日的研究报告中重申了对 Natera 的 “卖出（d-）” 评级。最后，Robert W. Baird 在 5 月 8 日的报告中将 Natera 的目标价设定为 265.00 美元。一位分析师对该股票给予了强烈买入评级，十四位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 256.60 美元。</p>
</div><p><strong>View Our Latest Analysis on NTRA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 NTRA 的最新分析</strong></p>
</div><h2>About Natera</h2>
<div class="lb-trans"><h2>关于 Natera</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.</p>
<div class="lb-trans"><p>Natera 是一家全球诊断公司，开发和商业化无细胞 DNA 及其他基因检测技术用于临床应用。该公司专注于三个主要领域：生殖健康（包括无创产前检测和携带者筛查）、肿瘤学（用于最小残留病和复发监测的肿瘤信息检测）以及器官移植（用于检测移植物损伤的无细胞 DNA 检测）。Natera 结合实验室检测、专有生物信息学和临床报告，为临床医生和患者提供个性化的基因信息。</p>
</div><p>Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.</p>
<div class="lb-trans"><p>主要产品包括 Panorama，一种无创产前检测，用于筛查胎儿染色体异常和特定单基因疾病；Horizon 携带者筛查，用于遗传疾病；Signatera，一种个性化的肿瘤信息检测，用于检测最小残留病和监测癌症患者的治疗反应；以及 Prospera，一种供体来源的无细胞 DNA 检测，用于评估器官排斥的风险。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Natera</li>
<li>3 Stocks Rallying on Micron's Price Boost: Substance or Hype?</li>
<li>Snowflake and the Snowballing Impact of its AI Flywheel</li>
<li>AI’s Biggest Bottleneck Could Make These 2 Stocks Soar</li>
<li>These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Natera 更好</li>
<li>3 只因美光价格上涨而上涨的股票：实质还是炒作？</li>
<li>Snowflake 及其 AI 飞轮的滚雪球效应</li>
<li>AI 的最大瓶颈可能使这两只股票飙升</li>
<li>这三只被打压的股票刚刚看到 2500 万美元的内部购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=NTRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Natera Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Natera 吗？</h2>
</div><p>Before you consider Natera, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Natera 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Natera 并不在名单上。</p>
</div><p>While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Natera 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

John Fesko Sells 1,438 Shares of Natera (NASDAQ:NTRA) Stock

Market Beat

Natera

万基遗传

摩根士丹利

摩根大通

富国银行

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

John Fesko 出售了 1,438 股 Natera（纳斯达克代码：NTRA）的股票